As Its Investors Reap Returns, San Francisco's Venbio Aims For A Bigger Second Fund

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

San Francisco life sciences venture firm venBio is making news these days with entrances and exits. Since its $180 million inaugural fund closed in 2011, two of its portfolio companies have become splashy acquisitions, including one last week. Thanks to those exits, venBio’s investors have more than broken even, and the group is now eyeing a run at a larger second fund up to $300 million, partner and cofounder Corey Goodman (pictured) told Xconomy.

Help employers find you! Check out all the jobs and post your resume.

Back to news